TY - JOUR
T1 - Pomalidomide
T2 - New immunomodulatory agent with potent antiproliferative effects
AU - Richardson, Paul G.
AU - Mark, Tomer M.
AU - Lacy, Martha Q.
N1 - Funding Information:
Paul Richardson has had a consultancy role for Celgene Corporation and Millennium Pharmaceuticals. Tomer Mark has received research funding and had a consultancy role for Celgene Corporation, and honoraria for participating on the speakers bureau for Celgene Corporation, Millennium Pharmaceuticals, and Sanofi-Aventis. Martha Lacy has received funding from Celgene Corporation.
PY - 2013/10/1
Y1 - 2013/10/1
N2 - New treatment options are urgently needed for patients with relapsed multiple myeloma (MM) who are refractory to thalidomide, lenalidomide, and bortezomib therapy. Pomalidomide, a second-generation immunomodulatory agent, has been shown to exert direct antiproliferative actions on MM cells, effects on the bone-marrow microenvironment, and immunomodulation. In phase I clinical trials, pomalidomide has demonstrated promising response rates in patients with relapsed and/or refractory MM, with manageable toxicity. In phase II trials pomalidomide, 2-4. mg/daily, given continuously or on days 1-21 of a 28-day cycle, in combination with dexamethasone, has been associated with high quality and durable clinical responses in patients who are refractory to lenalidomide, bortezomib, or both. Pomalidomide appears to be well tolerated; hematologic toxicities are the most commonly reported adverse events and peripheral neuropathy is rare. Phase III trials are currently underway to determine the optimal dose and combination regimen of pomalidomide in the treatment of MM.
AB - New treatment options are urgently needed for patients with relapsed multiple myeloma (MM) who are refractory to thalidomide, lenalidomide, and bortezomib therapy. Pomalidomide, a second-generation immunomodulatory agent, has been shown to exert direct antiproliferative actions on MM cells, effects on the bone-marrow microenvironment, and immunomodulation. In phase I clinical trials, pomalidomide has demonstrated promising response rates in patients with relapsed and/or refractory MM, with manageable toxicity. In phase II trials pomalidomide, 2-4. mg/daily, given continuously or on days 1-21 of a 28-day cycle, in combination with dexamethasone, has been associated with high quality and durable clinical responses in patients who are refractory to lenalidomide, bortezomib, or both. Pomalidomide appears to be well tolerated; hematologic toxicities are the most commonly reported adverse events and peripheral neuropathy is rare. Phase III trials are currently underway to determine the optimal dose and combination regimen of pomalidomide in the treatment of MM.
KW - Immunomodulatory agent
KW - Multiple myeloma
KW - Pomalidomide
UR - http://www.scopus.com/inward/record.url?scp=84882612996&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84882612996&partnerID=8YFLogxK
U2 - 10.1016/j.critrevonc.2013.02.001
DO - 10.1016/j.critrevonc.2013.02.001
M3 - Review article
C2 - 23786844
AN - SCOPUS:84882612996
SN - 1040-8428
VL - 88
SP - S36-S44
JO - Critical Reviews in Oncology/Hematology
JF - Critical Reviews in Oncology/Hematology
IS - SUPPL.1
ER -